Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yubin Kang

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Journal of Visualized Experiments : Jove|March 26, 2013
Using quantitative real-time PCR to determine donor cell engraftment in a competitive murine bone marrow transplantation modelNingfei An, Yubin Kang
Pharmacology & Therapeutics|September 28, 2021
Chimeric antigen receptor (CAR) T-cell therapy for multiple myelomaTaewoong Choi, Yubin Kang
Experimental Hematology & Oncology|December 6, 2012
Immune modulation therapy in the management of bortezomib-induced peripheral neuropathyAshley Jeter, Yubin Kang
Advances in Cancer Research|June 30, 2014
Thioredoxin and hematologic malignanciesNingfei An, Yubin Kang
Antioxidants (Basel, Switzerland)|July 27, 2022
Emerging Evidence of the Significance of Thioredoxin-1 in Hematopoietic Stem Cell AgingShaima Jabbar, Parker Mathews, Yubin Kang
Cellular Immunology|September 8, 2019
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myelomaDaniel Feinberg, Barry Paul, Yubin Kang
Cancer Medicine|May 16, 2018
The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocationPasupathi Sundaramoorthy, Cristina Gasparetto, Yubin Kang
Journal of Cancer Metastasis and Treatment|April 26, 2019
Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myelomaDustin Rizzieri, Barry Paul, Yubin Kang
Cancers|September 10, 2021
PIM Kinases in Multiple MyelomaJian Wu, Emily Chu, Yubin Kang
Journal of Hematology & Oncology|January 31, 2013
Abnormal hematopoietic phenotypes in Pim kinase triple knockout miceNingfei An, Andrew S Kraft, Yubin Kang
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Journal of Visualized Experiments : Jove|March 26, 2013
Using quantitative real-time PCR to determine donor cell engraftment in a competitive murine bone marrow transplantation modelNingfei An, Yubin Kang
Pharmacology & Therapeutics|September 28, 2021
Chimeric antigen receptor (CAR) T-cell therapy for multiple myelomaTaewoong Choi, Yubin Kang
Experimental Hematology & Oncology|December 6, 2012
Immune modulation therapy in the management of bortezomib-induced peripheral neuropathyAshley Jeter, Yubin Kang
Advances in Cancer Research|June 30, 2014
Thioredoxin and hematologic malignanciesNingfei An, Yubin Kang
Antioxidants (Basel, Switzerland)|July 27, 2022
Emerging Evidence of the Significance of Thioredoxin-1 in Hematopoietic Stem Cell AgingShaima Jabbar, Parker Mathews, Yubin Kang
Cellular Immunology|September 8, 2019
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myelomaDaniel Feinberg, Barry Paul, Yubin Kang
Cancer Medicine|May 16, 2018
The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocationPasupathi Sundaramoorthy, Cristina Gasparetto, Yubin Kang
Journal of Cancer Metastasis and Treatment|April 26, 2019
Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myelomaDustin Rizzieri, Barry Paul, Yubin Kang
Cancers|September 10, 2021
PIM Kinases in Multiple MyelomaJian Wu, Emily Chu, Yubin Kang
Journal of Hematology & Oncology|January 31, 2013
Abnormal hematopoietic phenotypes in Pim kinase triple knockout miceNingfei An, Andrew S Kraft, Yubin Kang
Pageof 9